Anaxis Pharma is developing novel small molecule therapeutics targeting necroptosis mediated cell death in inflammation to provide better therapies for patients suffering from inflammatory disorders. Blocking necroptosis targets the root cause of inflammation without causing immune suppression and holds significant promise as a new treatment paradigm differentiated from standard-of-care therapies. Our first in class inhibitors will enter the clinic in early 2025.